DOCETAXEL AND GEMCITABINE IN THE TREATMENT OF UNKNOWN PRIMARY TUMORS - A PHASE II STUDY -

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-000452-32-IT

Enrollment

Registered

2006-03-03

Start date

2005-05-03

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

FIRST LINE TREATMENT OF METASTATIC UNKNOWN PRIMARY TUMORS MedDRA version: 6.1 Level: HLT Classification code 10029105

Interventions

Trade Name: GEMZAR 1G POLV. EV 1 FL Pharmaceutical Form: Powder for infusion* INN or Proposed INN: Gemcitabine CAS Number: 122111-03-9 Concentration unit: g gram(s) Concentration type: equal Concentra

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Secondary Objective: ;Primary end point(s): ;Main Objective:	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026